Eli Lilly is at the head of the pharma pack today, but in a decade, the situation could look very different.

Lilly Employer Connect aims to make obesity treatments more predictable for employers while lowering costs for workers ...

With short-term returns turning negative, analysts are reassessing Lilly's high valuation, reminding the market that even ...

GLP-1 weight loss drugs are increasingly popular as a treatment for obesity. But a lot of employer-sponsored health plans won ...

Eli Lilly is making headlines in the pharmaceutical sector, but it's a very expensive stock.

Eli Lilly has been a growth beast in recent years, but its valuation has gotten fairly high along the way.

Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

Eli Lilly announced on "Good Morning America" Monday that its GLP-1 weight-loss drug Zepbound will now be available in a new ...

The company said the weight-loss drug will be available at the same self-pay price in either the single-dose vial format or ...

March 5 (Reuters) - Eli Lilly said on Thursday it has rolled out a platform to help employers connect with organizations ...

GoodRx Holdings will offer employers access to Eli Lilly's Zepbound through a new program designed to help companies manage the cost of weight-loss drugs. The prescription-drug provider said Friday ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now.